|
gptkbp:instanceOf
|
gptkb:drug
antiparkinsonian agent
monoamine oxidase inhibitor
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:ATCCode
|
N04BD03
|
|
gptkbp:brand
|
Xadago
|
|
gptkbp:CASNumber
|
gptkb:202825-46-5
|
|
gptkbp:chemicalClass
|
benzylamine derivative
|
|
gptkbp:contraindication
|
severe hepatic impairment
concomitant use with other MAO inhibitors
concomitant use with pethidine
|
|
gptkbp:developer
|
Newron Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
20-30 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C17H19FN2O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
safinamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Zambon
|
|
gptkbp:mechanismOfAction
|
MAO-B inhibition
glutamate release inhibition
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
320.34 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
fall
nausea
hypertension
insomnia
dyskinesia
|
|
gptkbp:usedFor
|
gptkb:Parkinson's_disease
|
|
gptkbp:bfsParent
|
gptkb:MAO-B
gptkb:monoamine_oxidase_B
|
|
gptkbp:bfsLayer
|
7
|